{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:21Z","timestamp":1791903321335,"version":"4.3.4"},"reference-count":40,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Von Willebrand factor (VWF) concentrate prophylaxis is recommended for patients with severe von Willebrand disease (VWD) or VWD with frequent bleeding symptoms but remains underused due, in part, to the high direct cost associated with regular concentrate administration. Robust cost-effectiveness data for VWF prophylaxis are limited, with most analyses relying on literature-based assumptions rather than prospective clinical data. A trial-based cost-effectiveness analysis was developed to estimate the long-term economic impact of plasma-derived VWF\/factor VIII (Wilate) prophylaxis vs on-demand therapy in patients with type 3 VWD in the United States, from both payer and societal perspectives. Clinical inputs were derived directly from phase 3 clinical studies, whereas health care costs were obtained from published sources. Productivity losses during bleeding events were incorporated into the societal analysis. Subgroup analyses were performed for adults and adult women with type 3 VWD, and evaluations were conducted for both 1-year and lifetime horizons. The payer analysis highlighted potential cost savings with Wilate prophylaxis across all groups, with estimated annual savings of $10\u2009898 per individual in the overall type 3 VWD cohort, $53\u2009264 among adults, and $125\u2009712 among women. Savings were higher in the societal perspective, with the largest benefit observed in women ($148\u2009555 per individual annually). The primary cost drivers were bleeding rates and treatment costs during on-demand therapy. In addition to its established clinical efficacy, these findings demonstrate a potential substantial economic advantage of Wilate prophylaxis and support broader adoption of VWF-based prophylaxis for individuals with type 3 VWD in the United States.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019994","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:30:37Z","timestamp":1783726237000},"page":"6719-6728","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Cost comparison of pdVWF\/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr.","given":"Robert F.","family":"Sidonio","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-7826","authenticated-orcid":false,"given":"Nathan T.","family":"Connell","sequence":"additional","affiliation":[{"name":"2Division of Global Health Equity, Department of Medicine, Mass General Brigham and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6185-4809","authenticated-orcid":false,"given":"Fernando F.","family":"Corrales-Medina","sequence":"additional","affiliation":[{"name":"3Division of Pediatric Hematology\/Oncology, Department of Pediatrics, University of Miami Miller School of Medicine and University of Miami Hemophilia and Thrombosis Comprehensive Treatment Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Longo","sequence":"additional","affiliation":[{"name":"4AESARA, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Shi","family":"Yeh","sequence":"additional","affiliation":[{"name":"4AESARA, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-7022","authenticated-orcid":false,"given":"Caroline","family":"Malcolmson","sequence":"additional","affiliation":[{"name":"5Division of Haematology\/Oncology, The Hospital for Sick Children, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"21","key":"2026101310433396900_bib1","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMra1601561","article-title":"Von Willebrand\u2019s Disease","volume":"375","author":"Leebeek","year":"2016","journal-title":"N Engl J Med"},{"key":"2026101310433396900_bib2","doi-asserted-by":"crossref","first-page":"20406207211064064","DOI":"10.1177\/20406207211064064","article-title":"Prophylactic management of patients with von Willebrand disease","volume":"12","author":"Franchini","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"1","key":"2026101310433396900_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/rth2.12468","article-title":"Sexism in the management of bleeding disorders","volume":"5","author":"Weyand","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"2026101310433396900_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/JBM.S389241","article-title":"Von Willebrand disease epidemiology, burden of illness and management: a systematic review","volume":"14","author":"Du","year":"2023","journal-title":"J Blood Med"},{"issue":"2","key":"2026101310433396900_bib5","first-page":"175","article-title":"Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States","volume":"27","author":"Lu","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"2026101310433396900_bib6","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/hae.13473","article-title":"Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network","volume":"24","author":"Holm","year":"2018","journal-title":"Haemophilia"},{"issue":"6","key":"2026101310433396900_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14737167.2023.2211270","article-title":"Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia","volume":"23","author":"Connell","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"2026101310433396900_bib8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13023-023-02690-w","article-title":"The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study","volume":"18","author":"Young","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"suppl 1","key":"2026101310433396900_bib9","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1097\/01.mbc.0000167659.23262.18","article-title":"Long-term prophylaxis in von Willebrand disease","volume":"16","author":"Berntorp","year":"2005","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2026101310433396900_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/bloodadvances.2020003264","article-title":"ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease","volume":"5","author":"Connell","year":"2021","journal-title":"Blood Adv"},{"issue":"14","key":"2026101310433396900_bib11","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1182\/bloodadvances.2025016512","article-title":"2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease","volume":"9","author":"James","year":"2025","journal-title":"Blood Adv"},{"key":"2026101310433396900_bib12","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.thromres.2020.12.030","article-title":"Translating the success of prophylaxis in haemophilia to von Willebrand disease","volume":"199","author":"Miesbach","year":"2021","journal-title":"Thromb Res"},{"issue":"1","key":"2026101310433396900_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2516.2012.02916.x","article-title":"Prophylaxis in severe forms of von Willebrand\u2019s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)","volume":"19","author":"Abshire","year":"2013","journal-title":"Haemophilia"},{"issue":"5","key":"2026101310433396900_bib14","first-page":"391","article-title":"A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF\/FVIII concentrates in severe inherited von Willebrand disease","volume":"17","author":"Peyvandi","year":"2019","journal-title":"Blood Transfus"},{"issue":"6","key":"2026101310433396900_bib15","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/bloodadvances.2023011742","article-title":"von Willebrand factor\/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease","volume":"8","author":"Sidonio","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026101310433396900_bib16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1182\/blood.2021014810","article-title":"Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results","volume":"140","author":"Leebeek","year":"2022","journal-title":"Blood"},{"issue":"11","key":"2026101310433396900_bib17","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/j.1538-7836.2006.02179.x","article-title":"The von Willebrand disease prophylaxis network: exploring a treatment concept","volume":"4","author":"Berntorp","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"suppl 1","key":"2026101310433396900_bib18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-136241","article-title":"Cost-effectiveness of long-term prophylaxis versus on-demand treatment with von Willebrand factor concentrate in severe inherited von Willebrand disease [abstract]","volume":"136","author":"Bhaskar","year":"2020","journal-title":"Blood"},{"issue":"suppl 3","key":"2026101310433396900_bib19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/hae.14956","article-title":"Diagnosis and treatment challenges in lower resource countries: state-of-the-art","volume":"30","author":"Mahlangu","year":"2024","journal-title":"Haemophilia"},{"issue":"6","key":"2026101310433396900_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2024014376","article-title":"Cost-effectiveness of voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom","volume":"9","author":"Wilson","year":"2025","journal-title":"Blood Adv"},{"key":"2026101310433396900_bib21","unstructured":"Wilate. Package insert. Accessed 17 November 2025. https:\/\/www.medicines.org.uk\/emc\/product\/2873\/smpc."},{"key":"2026101310433396900_bib22","unstructured":"Wilate. Prescribing information. Accessed 17 November 2025. https:\/\/wilateusa.com\/wp-content\/uploads\/2025\/09\/wilate-full-prescribing-information.pdf."},{"issue":"2","key":"2026101310433396900_bib23","doi-asserted-by":"crossref","first-page":"100501","DOI":"10.1016\/j.xagr.2025.100501","article-title":"Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor\/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls\/women with von Willebrand disease","volume":"5","author":"Kiss","year":"2025","journal-title":"AJOG Glob Rep"},{"key":"2026101310433396900_bib24","doi-asserted-by":"crossref","first-page":"10760296241306755","DOI":"10.1177\/10760296241306755","article-title":"Efficacy of wilate prophylaxis in reducing nosebleeds in patients with severe VWD \u2013 a post-hoc analysis of the WIL-31 study","volume":"30","author":"Boban","year":"2024","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"2026101310433396900_bib25","doi-asserted-by":"crossref","first-page":"102719","DOI":"10.1016\/j.rpth.2025.102719","article-title":"Efficacy and safety of plasma-derived von Willebrand factor\/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease \u2013 WIL-31 study post hoc analysis","volume":"9","author":"Sidonio","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"2026101310433396900_bib26","doi-asserted-by":"crossref","first-page":"100063","DOI":"10.1016\/j.hpopen.2021.100063","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"3","author":"Husereau","year":"2022","journal-title":"Health Policy OPEN"},{"key":"2026101310433396900_bib27","unstructured":"Bureau of Labor Statistics\n          . How BLS measures price change for medical care services in the consumer price index. Accessed 27 November 2025. https:\/\/www.bls.gov\/cpi\/factsheets\/medical-care.htm."},{"key":"2026101310433396900_bib29","unstructured":"Medi-Span: drug database solutions to strengthen healthcare decisions. Accessed 11 November 2025. https:\/\/www.wolterskluwer.com\/en\/solutions\/medi-span."},{"issue":"1","key":"2026101310433396900_bib30","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/hae.13634","article-title":"Utility valuation of health states for haemophilia and related complications in Europe and in the United States","volume":"25","author":"Hoxer","year":"2019","journal-title":"Haemophilia"},{"issue":"18","key":"2026101310433396900_bib31","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1182\/blood.2021010864","article-title":"The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective","volume":"138","author":"Bolous","year":"2021","journal-title":"Blood"},{"key":"2026101310433396900_bib32","unstructured":"The Centers for Disease Control and Prevention (CDC) National Center for Health Statistics\n          . FastStats. Updated 5 February 2026. Accessed 12 May 2026. https:\/\/www.cdc.gov\/nchs\/fastats\/life-expectancy.htm."},{"key":"2026101310433396900_bib33","unstructured":"Institute for Clinical and Economic Review\n          . Reference Case For Publication. Accessed 11 November 2025. https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/ICER_Reference-Case_For-Publication_102325.pdf."},{"issue":"1","key":"2026101310433396900_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/00043764-200101000-00005","article-title":"Alternative valuations of work loss and productivity","volume":"43","author":"Berger","year":"2001","journal-title":"J Occup Environ Med"},{"issue":"4","key":"2026101310433396900_bib35","first-page":"211","article-title":"A review of methods to measure health-related productivity loss","volume":"13","author":"Mattke","year":"2007","journal-title":"Am J Manag Care"},{"key":"2026101310433396900_bib36","unstructured":"Statista\n          . Monthly average earnings per hour of all employees in the United States from May 2024 to May 2026 (in U.S. dollars). Accessed 11 November 2025. https:\/\/www.statista.com\/statistics\/215630\/hourly-earnings-of-all-employees-in-the-us-by-month\/."},{"issue":"2","key":"2026101310433396900_bib37","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hec.1052","article-title":"Measuring the effects of work loss on productivity with team production","volume":"15","author":"Nicholson","year":"2006","journal-title":"Health Econ"},{"key":"2026101310433396900_bib38","first-page":"12","author":"Linden","year":"2023"},{"key":"2026101310433396900_bib39","unstructured":"Institute for Clinical and Economic Review\n          . Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value. Accessed 8 June 2026. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Hemophilia-A_Evidence-Report_102620.pdf."},{"issue":"4","key":"2026101310433396900_bib40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/MBC.0000000000000257","article-title":"Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network","volume":"26","author":"Holm","year":"2015","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2026101310433396900_bib41","unstructured":"National Heart Lung and Blood Institute\n          . The Diagnosis, Evaluation, and Management of von Willebrand Disease. 2007. Accessed 11 November 2025. https:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/vwd.pdf."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6719\/2592934\/blooda_adv-2026-019994-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6719\/2592934\/blooda_adv-2026-019994-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:47Z","timestamp":1791902627000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6719\/569668\/Cost-comparison-of-pdVWF-FVIII-prophylaxis-and-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":40,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019994","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,30]]}}}